Latest news on BioNTech's Friday buyout; Unpacking Sarepta’s Duchenne data; Pfizer’s post-Covid plans; Eli Lilly, AstraZeneca's gene editing deals; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
With earnings seasons in full swing, the Endpoints team worked hard to stay on top of Big Pharma’s latest updates as well as breaking news. Don’t miss our analysis on what a standing ovation-worthy data readout at ESMO means for future clinical trials, the FDA’s shift toward asking for more overall survival data and a Q&A about biotech interests on Capitol Hill.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.